Spero Therapeutics (SPRO) Share-based Compensation (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Share-based Compensation came in at $1.1 million in Q1 2026, down 28.41% YoY from $1.6 million in Q1 2025, and up 10.63% on a QoQ basis from $1.0 million in Q4 2025.
Spero Therapeutics (SPRO) Share-based Compensation (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Share-based Compensation data on file, last reported at $1.1 million in Q1 2026.
- Quarterly Share-based Compensation fell 28.41% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (down 47.0% YoY) and the FY2025 annual result came in at $4.3 million, down 44.5% from the prior year.
- Share-based Compensation improved to $1.1 million in Q1 2026, from $1.0 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $3.2 million in Q1 2022 to a low of $714000.0 in Q2 2025.
- A 5-year average of $1.8 million and a median of $1.9 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation jumped 59.43% — and 2025, when it tumbled 66.21%.
- Tracing SPRO's Share-based Compensation over 5 years: stood at $2.5 million in 2022, then slipped by 20.02% to $2.0 million in 2023, then dropped by 24.74% to $1.5 million in 2024, then tumbled by 33.0% to $1.0 million in 2025, then advanced by 10.63% to $1.1 million in 2026.
- The last three Share-based Compensation figures came in at $1.1 million (Q1 2026), $1.0 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | 822,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 822,000.00 |
| Jun 30, 2026 | 822,000.00 |
| Mar 31, 2026 | 1.11 Mn |
| Mar 31, 2026 | 1.11 Mn |
| Dec 31, 2025 | 1.01 Mn |
| Dec 31, 2025 | 1.01 Mn |
| Sep 30, 2025 | 1.05 Mn |
| Sep 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | 714,000.00 |
| Jun 30, 2025 | 714,000.00 |
| Mar 31, 2025 | 1.56 Mn |
| Mar 31, 2025 | 1.56 Mn |
| Dec 31, 2024 | 1.50 Mn |
| Dec 31, 2024 | 1.50 Mn |
| Sep 30, 2024 | 2.15 Mn |
| Sep 30, 2024 | 2.15 Mn |
| Jun 30, 2024 | 2.11 Mn |
| Jun 30, 2024 | 2.11 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Mar 31, 2024 | 2.02 Mn |